We are developing a series of drugs to improve overall survival in acute myeloid leukemia patients

MaaT013 – Steroid-Refractory Acute Graft-Versus-Host Disease (SRaGvHD) program – enema

Heracles Study

› Evaluation of Complete Response (CR) or Very Good Partial Response (VGPR) of Steroid Refractory, Gastrointestinal, Acute Graft-Versus-Host Disease (SRaGvHD) treated with MaaT013 (pooled donors)› First Patient In (FPI): august 2018
3 Positive DSMBs (first 15 Patients) –> Study continuing without amendments

Odyssee Study

Efficacy of enema-based autologous approach in:
 Dysbiosis correction
 Eradication of multi-drug resistant bacteria in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR MDS) undergoing chemotherapy and antibiotherapy
Intermediary results presented during the ASH congress in 2017
› 2 positive DSMB (Data Safety Monitoring Board)
› 25 treated patients
› End of one year follow-up completed

Main Results

  • Excellent safety profile with 84% survival after one year
  • 90% reconstruction of the microbiome (Simpson diversity index; p=0.0001).
  • Reduction of 43% of genes coding for anti-microbial resistance
More info on clinicaltrials.gov

* AML: Acute Myeloid Leukemia
* MDS: MyeloDysplastic Syndromes

MaaT 033 – Oral Form – improvement of overall survival in hematological patients

Cimon Study

 Optimal dose
In preparation

What are Hematological Malignancies?

They are rare cancers (also know as blood cancers) that affect the blood, bone marrow, lymph and lymphatic system. These cancers are subdivided according to which type of blood cells are affected:
Lymphoblastic or lymphocytic: a malignancy in the lymphoid lineage that produces white blood cells such as T and B lymphocytes. Examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s and Non-Hodgkin lymphomas and multiple myeloma.
Myelogenous or myeloid: a malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells. Examples include acute myelogenous leukemia, chronic myeloid leukemia and myelodysplastic syndromes.
The classification also includes how quickly the disease develops and worsens (acute versus chronic).

 For example, there are 4 major types of leukemia:

  • Acute Lymphocytic leukemia
  • Chronic Lymphocytic leukemia
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia

What is the worldwide estimated incidence and mortality (2012) ?

    Incidence (% all cancers)        Mortality (% all cancers)
Leukemia351 965 (2.5%)265 471 (3.2%)
Hodgkin’s Lymphoma65 950 (0.5%)25 469 (0.3%)
Non-Hodgkin’s Lymphoma385 741 (2.7%)199 670 (2.4%)
Multiple Myeloma114 251 (0.8%)80 019 (1.0%)

Source – globocan.iarc.fr / 2012

These diseases are increasingly found in patients aged 65 and over. The survival of these conditions including those deemed incurable and the quality of life of people with the disease have been improved in recent years.

Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.

We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.